Your browser is no longer supported. Please, upgrade your browser.
Settings
CLSN Celsion Corporation daily Stock Chart
CLSN [NASD]
Celsion Corporation
Index- P/E- EPS (ttm)-0.90 Insider Own0.80% Shs Outstand28.40M Perf Week-44.41%
Market Cap7.10M Forward P/E- EPS next Y-0.57 Insider Trans49.28% Shs Float27.36M Perf Month-38.42%
Income-22.20M PEG- EPS next Q-0.19 Inst Own16.10% Short Float9.30% Perf Quarter-70.93%
Sales0.50M P/S14.20 EPS this Y25.40% Inst Trans51.53% Short Ratio1.68 Perf Half Y-80.16%
Book/sh0.38 P/B0.66 EPS next Y32.90% ROA-51.20% Target Price3.00 Perf Year-80.16%
Cash/sh0.31 P/C0.82 EPS next 5Y- ROE-141.30% 52W Range0.19 - 1.78 Perf YTD-17.74%
Dividend- P/FCF- EPS past 5Y31.50% ROI- 52W High-85.96% Beta1.37
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low35.14% ATR0.06
Employees25 Current Ratio0.90 Sales Q/Q0.00% Oper. Margin- RSI (14)36.66 Volatility20.84% 12.39%
OptionableYes Debt/Eq0.34 EPS Q/Q-23.90% Profit Margin- Rel Volume3.71 Prev Close0.23
ShortableNo LT Debt/Eq0.00 EarningsMar 29 BMO Payout- Avg Volume1.51M Price0.25
Recom2.00 SMA20-32.19% SMA50-38.73% SMA200-75.19% Volume5,615,178 Change9.51%
Nov-10-16Downgrade Maxim Group Buy → Hold
Jul-12-16Resumed H.C. Wainwright Buy $3
Jan-19-16Reiterated Maxim Group Buy $12 → $9
Jul-15-15Initiated Maxim Group Buy $12
Jan-10-14Resumed HC Wainwright Buy $5 → $8
Aug-16-12Reiterated Griffin Securities Buy $10 → $18
Feb-16-12Initiated Brean Murray Buy $7
Oct-26-11Initiated Rodman & Renshaw Mkt Outperform $6
Nov-11-09Initiated Needham Buy $7
Feb-15-17 07:13AM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -33.33%
07:00AM  Celsion Corporation Announces $5.0 Million Public Offering GlobeNewswire
Jan-27-17 04:43PM  CELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-19-17 12:40PM  ETFs with exposure to Celsion Corp. : January 19, 2017
08:00AM  Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Jan-18-17 08:00AM  Celsion Corporation Announces Issuance of Two New Patents for ThermoDox® GlobeNewswire -19.41%
Jan-17-17 08:00AM  Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients GlobeNewswire +30.77%
Dec-23-16 03:02PM  CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Dec-22-16 01:12PM  ETFs with exposure to Celsion Corp. : December 22, 2016
Dec-20-16 03:37PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -25.13%
02:45PM  Celsion Corporation Announces $1.8 Million Registered Direct Offering GlobeNewswire
Dec-16-16 01:30PM  Celsion Corporation Announces Progress with ThermoDox® Development Efforts in China and Asia Pacific GlobeNewswire -7.86%
Dec-01-16 08:00AM  Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer GlobeNewswire
Nov-30-16 08:00AM  Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer GlobeNewswire -13.07%
Nov-29-16 08:00AM  Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting GlobeNewswire
Nov-18-16 01:04PM  CELSION CORP Financials
Nov-16-16 12:58PM  ETFs with exposure to Celsion Corp. : November 16, 2016 +5.52%
Nov-15-16 11:47AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
Nov-10-16 03:10PM  Celsion downgraded by Maxim Group
08:30AM  Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients GlobeNewswire
08:13AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q3 2016 Celsion Corp Earnings Release - Time Not Supplied
Nov-04-16 08:00AM  Celsion Corporation Announces Issuance of Two New U.S. Patents for its GEN-1 Immuno-Oncology Product GlobeNewswire
Nov-03-16 08:00AM  Celsion Corporation to Hold Third Quarter 2016 Financial Results Conference Call on Thursday, November 10, 2016 GlobeNewswire -9.18%
Oct-31-16 09:00AM  Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate Primary Liver Cancer at the 3rd Asian Conference on Tumor Ablation (ACTA) GlobeNewswire
Oct-13-16 09:37AM  ETFs with exposure to Celsion Corp. : October 13, 2016
Oct-11-16 08:00AM  Celsion Announces Collaboration with the Childrens Research Institute to Evaluate the Use of ThermoDox® and High Intensity Focused Ultrasound in the Treatment of Solid Tumors in Children and Young Adults GlobeNewswire
Sep-15-16 08:00AM  Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer GlobeNewswire
Sep-12-16 10:41AM  ETFs with exposure to Celsion Corp. : September 12, 2016
08:00AM  Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer GlobeNewswire
Sep-08-16 04:32PM  CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers
Sep-07-16 08:00AM  Celsion Corporation to Present at Upcoming Investor Conferences GlobeNewswire
Aug-30-16 11:02AM  ETFs with exposure to Celsion Corp. : August 30, 2016
Aug-19-16 12:46PM  ETFs with exposure to Celsion Corp. : August 19, 2016
Aug-18-16 11:04AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-15-16 09:14AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
09:00AM  Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
08:00AM  Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer GlobeNewswire
07:07AM  Q2 2016 Celsion Corp Earnings Release - Time Not Supplied
Aug-09-16 09:00AM  Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy GlobeNewswire
Aug-08-16 08:00AM  Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016 GlobeNewswire
Jul-25-16 08:00AM  Celsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients GlobeNewswire
Jul-20-16 12:16PM  ETFs with exposure to Celsion Corp. : July 20, 2016
Jul-17-16 10:35AM  4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside at 24/7 Wall St.
Jul-11-16 08:00AM  Celsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver Cancer Expert Meeting GlobeNewswire
Jul-07-16 08:00AM  Celsion Corporation to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference GlobeNewswire
Jun-21-16 08:00AM  Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic Oncology Peer-Reviewed Article GlobeNewswire
Jun-17-16 05:01PM  CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Jun-15-16 04:54PM  CELSION CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matte
Jun-13-16 02:06PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:03PM  Celsion Corporation Announces $6 Million Registered Direct Offering GlobeNewswire
Jun-07-16 11:08AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
Jun-01-16 05:10PM  CELSION CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
May-24-16 08:00AM  Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting PR Newswire
May-16-16 08:18AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update PR Newswire
May-09-16 08:57AM  Should You Buy Celsion (CLSN) Ahead of Earnings?
08:00AM  Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016 PR Newswire
May-06-16 08:14AM  ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise? Zacks
May-02-16 08:00AM  Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study PR Newswire
Apr-26-16 08:00AM  Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China PR Newswire
Apr-19-16 08:00AM  Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil® PR Newswire +7.45%
Apr-12-16 08:00AM  Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer PR Newswire +5.22%
Apr-06-16 11:56AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers
09:23AM  Celsion Corp. :CLSN-US: Earnings Analysis: 2015 By the Numbers
Apr-01-16 09:49AM  Edited Transcript of CLSN earnings conference call or presentation 30-Mar-16 3:00pm GMT
Mar-30-16 11:00AM  Celsion Corp Earnings Call scheduled for 11:00 am ET today
08:28AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update PR Newswire
Mar-23-16 08:14AM  Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016 at noodls
08:00AM  Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016 PR Newswire
Mar-16-16 04:35PM  Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® at the AACR Annual Meeting 2016 PR Newswire -5.71%
Mar-15-16 03:44PM  [$$] Cancer Therapy May See Major Shift at Barrons.com
Mar-07-16 08:00AM  Celsion Corporation Announces Launch of the OPTIMA Study in China PR Newswire +9.16%
Mar-01-16 08:00AM  Celsion Corporation Announces Issuance of Key U.S. Patent Covering its Novel TheraSilence RNA Program PR Newswire
Feb-15-16 03:20PM  Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus
Feb-12-16 08:00AM  Celsion Corporation Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update PR Newswire
Jan-07-16 08:00AM  Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer PR Newswire
Jan-05-16 01:00PM  Exelixis Reveals Data on Cabozantinib for Kidney Cancer
Dec-17-15 08:21AM  CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:00AM  Celsion Announces Appointment of Two New Members to Its Board of Directors PR Newswire
Dec-16-15 08:00AM  Celsion Receives CFDA Approval to Conduct the OPTIMA Study in China PR Newswire
Dec-14-15 08:00AM  Celsion Announces Presentation of DIGNITY Phase I/II ThermoDox® Data at the 2015 San Antonio Breast Cancer Symposium PR Newswire
Dec-09-15 09:30AM  New Strong Buy Stocks for December 9th
Nov-24-15 09:30AM  New Strong Buy Stocks for November 24th
08:00AM  Celsion Corporation to Present at the LD Micro Main Event Investor Conference PR Newswire
Nov-11-15 06:00PM  Celsion Corporation Announces Dual Listing on the Tel Aviv Stock Exchange PR Newswire
Nov-05-15 08:12AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports Third Quarter 2015 Financial Results and Provides Business Update PR Newswire
Nov-03-15 08:00AM  Celsion Corporation Names Edwin De Wit, M.D. as Senior Vice President and Head of Medical, Europe PR Newswire
Nov-02-15 08:00AM  Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate HCC at the 2nd Asian Conference on Tumor Ablation (ACTA) PR Newswire +9.36%
Oct-29-15 08:00AM  Celsion Corporation to Hold Third Quarter 2015 Financial Results Conference Call on Thursday, November 5, 2015 PR Newswire
Oct-15-15 08:00AM  Celsion to Host Research and Development Day on October 27, 2015 PR Newswire
Oct-14-15 04:50PM  Celsion (CLSN) Announces Data on Immunotherapy Candidate
Oct-12-15 08:00AM  Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® for Ovarian Cancer PR Newswire
Oct-06-15 08:00AM  Celsion Announces Upcoming Presentations at the 2nd Asian Conference on Tumor Ablation on October 30-31, 2015 PR Newswire
Oct-02-15 05:08PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-01-15 05:46PM  Celsion Begins Patient Enrollment in Ovarian Cancer Study
11:09AM  Celsion Corp. Earnings Q2, 2015
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company also has a collaboration with the Children's Research Institute to conduct a clinical study of ThermoDox, a heat activated liposomal encapsulation of doxorubicin in combination with magnetic resonance-guided high intensity focused ultrasound to treat relapsed or refractory solid tumors in children and young adults. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martinez Alberto R JrDirectorFeb 15Buy0.2245,0009,675145,081Feb 16 11:35 AM
Martinez Alberto R JrDirectorNov 14Buy0.8610,0008,600100,081Nov 14 12:49 PM
Martinez Alberto R JrDirectorNov 11Buy0.9110,0009,10090,081Nov 14 10:21 AM
Tardugno Michael HChairman, President and CEOOct 07Buy1.1410,00011,400143,021Oct 11 09:13 AM
Martinez Alberto R JrDirectorAug 16Buy1.255,0006,25080,081Aug 17 09:11 AM
Tardugno Michael HChairman, President and CEOAug 16Buy1.255,0006,245133,021Aug 17 09:11 AM
Martinez Alberto R JrDirectorJun 17Buy1.355,0006,75075,081Jun 17 10:50 AM
Tardugno Michael HChairman, President and CEOJun 16Buy1.357,50010,125128,021Jun 16 04:52 PM